PDCD1 and non-small cell lung carcinoma: A study conducted by AstraZeneca to assess the safety and efficacy of an anti-TIGIT/anti-PD-1 bispecific antibody, AZD2936, in NSCLC is currently in a Phase II trial (NCT04995523).